



The Role of Interleukin-6 in Anemia of Patients with Chronic Kidney Disease, in Pre-dialysis Stage

**Eman Ahmed Mohamed Esmail ^{a*}, Mohamed A. Safa ^a, Noha E. Esheba ^a,
Amira Y. Abd-Elnaby ^b and Hegazy Mohamed Hegazy ^a**

^a *Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt.*

^b *Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.*

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JAMMR/2022/v34i1031356

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/85120>

Received 05 February 2022

Accepted 02 April 2022

Published 21 April 2022

Original Research Article

ABSTRACT

Background: Anemia is common in chronic kidney patients. Interleukin-6 plays an important role in anemia. No studies were performed on the role of Interleukin-6 in anemia of pre-dialysis adult chronic kidney disease, so we performed this study to highlight this point.

Methods: A case control study conducted on 50 patients with CKD and 30 apparently healthy volunteers as a control group. They were further subdivided into: 1a: 12 CKD patients with Hb >10 and 1b: 38 CKD patients with moderate or severe anemia. Hb <10 gm/dl. Group 2: 30 healthy volunteers. All participants were subjected to full history taking, complete clinical examination, routine laboratory investigations including CBC, KFTs, LFTs and serum IL6 assay by ELIZA.

Results: Hb, HCT and MCV were significantly lower among group 1a and group 1b patients in comparison to group II, but CKD patients' groups had significantly higher IL-6 level than control group with no significant difference between patients' groups (group 1a and group 1b). Significant negative correlation was detected between IL6 and both Hb and HCT among patients and control group.

Conclusions: IL6 is significantly higher in chronic kidney patients in comparison to controls. It also correlates negatively with hemoglobin level and hematocrit. IL6 has a good sensitivity of 83.3% at a cutoff value of 74.7ng/l. So, it can be used as a prognostic marker of anemia in chronic kidney patients.

Keywords: Chronic kidney diseases; IL6; anemia.

1. INTRODUCTION

Chronic Kidney Disease (CKD) is a major public health issue that affects people all over the world. It affects the older people the most. While younger patients with CKD often have progressive loss of renal function, 30% of people with CKD over the age of 65 maintain stable illness [1]. According to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines, anemia in adults with CKD is diagnosed when hemoglobin (Hb) concentration is <13.0 g/dl in males and <12.0 g/dl in females. Many CKD patients have functional iron insufficiency, which is defined by inadequate iron release from body reserves that is insufficient to meet erythropoiesis requirement [2]. Anemia can also be caused by a reduction in red blood cell survival. Many studies imply that high hepcidin levels are to blame for poor dietary iron absorption and reticuloendothelial cell iron blockage, both of which are common in CKD patients [3]. In the event of tissue damage, Interleukin-6 (IL-6) also sends out a warning signal. Damage-associated molecular patterns (DAMPs), which are generated by damaged or dying cells in noninfectious inflammations such as burns or trauma, increase inflammation either directly or indirectly [4]. IL-6 is also involved in the regulation of serum iron level via control of its transporter. IL-6 induces hepcidin production, that blocks the action of iron transporter ferroprotein 1 on gut and thus, decreases serum iron levels. This means that the IL-6-hepcidin axis is responsible for hypoferremia and anemia associated with chronic inflammation [5]. In adult patients with CKD, circulating levels of IL-6 are inversely related to glomerular filtration rate (GFR). In adult patients initiating peritoneal and hemodialysis, IL-6 is an independent predictor of death [6]. When activated in vitro, peripheral blood mononuclear cells from hemodialysis patients generated more IL-6 than those from healthy people. In paediatric dialysis patients, IL-6 levels are high [7]. However, no studies addressed the role of IL-6 in anemia development in adult pre-dialysis CKD patients. That signifies the importance of this work.

2. PATIENTS AND METHODS

This case control study was conducted on 50 patients who had CKD. The patients were recruited from the outpatient clinic and wards of the Internal Medicine Department, Tanta

University Hospital. The study duration started from August 2019 to February 2020. Also 30 apparently healthy volunteers were enrolled as a control group. Participants were divided into the following groups: Group 1 (50 CKD patients), they were further subdivided into group 1a (12 CKD patients with mild anemia $12 > \text{Hb} > 10$) and group 1b (38 CKD patients with moderate or severe anemia, $\text{Hb} < 10$ gm/dl). And Group 2 (30 healthy volunteers as a control group).

2.1 Inclusion Criteria

Patients ≥ 18 years who had estimated glomerular filtration rate (eGFR) 15-60 ml/min/1.73 m².

2.2 Exclusion Criteria

Patients with any of the following conditions were excluded from the study: hemolytic conditions, chronic inflammatory diseases (e.g. rheumatoid arthritis), chronic blood loss (e.g. bleeding hemorrhoids), end-stage renal disease (ESRD) requiring dialysis, eGFR <15 ml/min/1.73 m² or malignant disease.

3. METHODS

All the participants were subjected to: Full history taking including: personal history, present history, family history, history of comorbidities and history of drug intake. Clinical examination including: General examination, local abdominal examination.

Investigations including: Routine laboratory investigations including: complete blood count (CBC), aspartate transaminase (AST), alanine transaminase (ALT), serum protein, serum albumin, blood urea, serum creatinine, eGFR, fasting blood glucose, 2 hours post prandial blood glucose and IL 6 assay by enzyme-linked immunosorbent assay (ELISA) using Sun red KIT (Cat. No. 201-12-0091 201-12-0091). Serum iron, serum ferritin and parathyroid hormone were measured in patients only. Pelvi-abdominal ultrasound.

3.1 Sample Collection & Storage

5 ml of venous blood were withdrawn from each subject under complete aseptic condition, and divided into 1ml collected on EDTA tube for CBC analysis and 4ml collected on a dry vacutainer

for the performance of the lab assays they were left to clot, then centrifuged at 3000 g for 10 min. Serum were separated into two separate aliquots. The first aliquot was used for lab analysis of aspartate transaminase (AST), alanine transaminase (ALT), serum protein, serum albumin, blood urea, serum creatinine, eGFR, fasting blood glucose, 2 hours post prandial blood glucose, the second aliquot was immediately frozen at -70°C for analysis of IL6 and avoid repeated freeze-thaw cycles.

3.2 ELISA Technique

Before using, all reagents and samples were brought to room temperature. All standards, controls, and samples were assayed in duplicate.

The kit uses a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human Interleukin 6(IL-6) in samples. Add 6(IL-6) to monoclonal antibody Enzyme well which is pre-coated with Human Interleukin 6(IL-6) monoclonal 6(IL-6) antibody, incubation; then, add Interleukin 6(IL-6) antibodies labeled with biotin, combined with Streptavidin-HRP to form immune complex; then carry out incubation and washing again to remove the uncombined enzyme. The colour of the liquid changes to blue when Chromogen Solution A, B is added, and the colour eventually turns yellow due to the acid impact. Color chroma and sample concentrations of Human Substance Interleukin 6(IL-6) were shown to be favourably linked.

3.3 Statistical Analysis

Data were collected throughout history. After that, the data was analysed using the Statistical Package for the Social Sciences (SPSS version 20.0). The following tests were employed to test for significance of differences based on the kind of data: qualitative data was represented as number and percentage, quantitative data was represented as mean and SD. The Chi square test was used to determine the difference and relationship between qualitative variables. Differences between quantitative independent groups using the t test or Mann Whitney test, correlation using Pearson's correlation or Spearman's correlation, and cutoff value using the ROC curve. Significant results were given a P value of <0.05.

4. RESULTS

The demographic data of the participants and some laboratory investigations were mentioned

in (Table 1). Serum albumin, serum protein and eGFR were significantly lower among patients both groups (group Ia and group Ib) than Group II with no significant difference between patients' groups. Blood urea and serum creatinine were significantly higher among patients' groups (group Ia and group Ib) than group II (control) with no significant difference between patients' groups. No significant difference was detected on comparing FBG and 2h PPG in the studied groups. (Table 1)

Regarding some CBC parameters, hemoglobin (Hb), hematocrit (HCT) and mean corpuscular volume (MCV) were significantly lower in Group Ib when compared to groups Ia and Group II, while white blood cells (WBCs) were significantly higher in Group Ib than in group Ia and Group II, but there was no significant difference regarding platelets count in all groups. As for IL6, it was significantly higher in groups Ia and Ib in comparison to controls, but the difference between group Ia and Ib did not reach statistical significance. (Table 2)

When we studied the levels of serum iron, serum ferritin and parathyroid hormone (PTH) in CKD patients, there was non-significant difference between the two groups (Table 3).

On studying the correlation between IL-6 and the studied parameters, we found a significant negative correlation between IL6 and Hb, hematocrit (HCT) among CKD patients. On the other hand, the remaining studied parameters showed no correlation with IL-6 (Table 4).

We performed receiver operating characteristic (ROC) Curve for IL-6 which revealed 83.3% sensitivity and 67.7% specificity in detection of anemia in CKD patients at a cutoff value >74.7ng/l of IL-6 with area under the curve= 0.71 (Fig. 1).

5. DISCUSSION

Chronic kidney disease (CKD) is a major public health issue that affects people all over the world. The elderly are more likely to develop CKD. While younger patients with CKD often have progressive loss of renal function, 30% of people with CKD over the age of 65 maintain stable illness [1]. However, very few studies have evaluated IL-6 in adults with pre-dialysis CKD, so this study was designed to study the role of interleukin 6 in anemia of pre-dialysis chronic kidney disease.

Table 1. Demographic and some laboratory data of the studied groups

Parameter	Group I (N=50)	Group II (N=30)		
Sex (M/F)	25/25	11/19		
Age (years)	52.9±9.33	49.51±7.11		
	Group Ia (N=12)	Group Ib (N=38)	Group II	P
ALT(IU/l)	21.5±8.05 P1=0.917 P2=0.166 P3=0.111	21.79±7.05	19.1±3.56	0.265
AST(IU/l)	23.25±7.65 P1=0.743 P2=0.141 P3=0.02	22.42±7.52	26.07±4.21	0.075
Serum protien(g/dl)	6.45±2.23 P1=0.285 P2=0.005 P3<0.001	6.01±1.23	7.267±0.54	<0.0001
Albumin(g/dl)	3.3±0.65 P1=0.476 P2<0.0001 P3<0.0001	3.153±0.73	4.27±.74	<0.0001
Blood urea(mg/dl)	104.1±36.88 P1=0.452 P2<0.0001 P3<0.0001	116.7±37.65	20.96±6.87	0.0001
Serum creatinine(mg/dl)	3.183±1.28 P1=0.267 P2<0.0001 P3<0.0001	3.793±1.24	0.74±0.13	<0.0001
eGFR(ml/min/1.73m ²)	31.12±16.97 P1=0.561 P2<0.0001 P3<0.0001	28.51±16.54	134.1±31.16	<0.0001
FBG (mg/d)	94.58±15.84 P1=0.643 P2=0.679 P3=0.391	92.66±16.3	95.58±14.34	0.688
2HPPG (mg/dl)	162.8±71.34 P1=0.739 P2=0.430 P3<0.321	181.3±72.5	124.2±54.3	0.432

Table 2. Comparison of some CBC parameters and IL-6 level in the studied groups

Parameter	Group Ia (N=12)	Group Ib (N=38)	Group II	P
Hb (g/dl)	10.15 ±2.03 P1<0.0001 P2<0.0001 P3<0.0001	8.37±1.08	12.4±1.24	0.001
Hematocrit (%)	31.84±3.47 P1<0.0001 P2<0.0001 P3<0.0001	25.66±3.32	37.33±3.61	<0.0001
MCV (fl)	55.27±9.65 P1=0.0008 P2<0.0001 P3<0.0001	44.94±9.71	80.06±5.13	<0.0001
WBCs (×10 ³)/mm ³	8325±2.8 P1=0.24 P2=0.022 P3=0.88	7345±2.5	6447±1.91	0.049
platelets (×10 ³)/mm ³	298667±92.6 P1=0.914 P2=0.563 P3=0.871	287737±91.6	277400±87.8	0.964
IL6(ng/l)	52.81±29.6 P1=0.654 P2=0.019 P3=0.006	63.73±28.7	34.3±14.89	0.006

Table 3. Comparison of serum iron, serum ferritin and PTH levels in CKD patients

	Group Ia	Group Ib	t	P
Serum iron (µg/dl)	0.693	0.43	1.56	0.125
Serum ferritin (µg/dl)	108.3	55.81	1.92	0.061
PTH (pg/ml)	198.2	192.4	10.262	0.795

Table 4. Correlation of IL-6 with the studied parameters in CKD patients

Parameter	IL-6 in CKD patients	
	r	P
Hb(g/dl)	-0.333	0.003
Hematocrit (%)	-0.286	0.043
MCV (fl)	-0.144	0.320
MCH (pg)	0.219	0.126
Iron(µg/dl)	0.004	0.976
Ferritin(µg/dl)	0.023	0.876
WBCs (×10 ³)/mm ³	0.134	0.355
PLTs (×10 ³)/mm ³	0.059	0.685
Cr(mg/dl)	0.134	0.352
eGFR(ml/min/1.73m ²)	0.007	0.961
PTH (pg/ml)	0.185	0.197




Fig. 1. ROC Curve for of IL-6. At a cutoff value >74.7ng/l of IL-6 it had 83.3% sensitivity and 67.7% specificity

This study was conducted on 50 patients who had CKD, in addition to 30 healthy volunteers who were enrolled as a control group. Patients were recruited from the outpatient clinic and wards of the Internal Medicine Department, Tanta University Hospitals during the period from August 2019 to February 2020.

In the current study, the mean hemoglobin level in groups Ia and Ib were significantly lower in comparison to controls. The same findings were recorded as regard the hematocrit.

Raj et al. [8] reported that 76% of their studied CKD patients had anemia compared to 6.7% of controls. They attributed that to inadequate synthesis of erythropoietin mediated by renal insufficiency and the anti-proliferative effects of accumulating uremic toxins. Those were the primary cause of anemia in ESRD.

The mean IL6 in group Ia patients was 52.81±29.6 ng/l, 63.73±28.7 ng/l in group Ib patients and 34.3±14.89 ng/l in control group with significant difference, this significant difference between patients and controls regarding IL6 may be responsible for the high prevalence of anemia among cases.

Inflammation causes macrophages to produce IL-6, which interacts on hepatocytes to induce hepcidin production [9]. In contrast, Ewelina et al. [10] did not find a statistically significant

difference in IL-6 levels in individuals with and without iron deficiency in their investigation. However, only in the group with absolute iron shortage did IL-6 levels rise as renal function deteriorated. Shu et al. [11] found that IL-6 levels rose in individuals with tumor-related anaemia, but that there was no link between IL-6 and hepcidin in patients with iron deficient anaemia. They speculated that iron deficiency, rather than inflammation, may have a greater impact on lowering hepcidin levels. Lower iron concentration was related with elevated serum IL-6 in healthy Japanese people, according to Nakagawa H et al. [12].

Przybyszewska et al. [13] found a considerably greater concentration of IL-6 in patients with chronic illness anaemia than in patients with iron deficiency anaemia, which is consistent with our findings. Inflammatory cytokines, including IL-6, appear to blunt the response to erythropoietin in patients with ESRD [14].

Barreto et al. 2010 [15]. illustrated that in the elderly and CKD patients on dialysis, IL-6 levels tended to rise as CKD progressed with the increase becoming statistically significant at CKD stages 5.

A study conducted by Malaponte et al. [16] showed that the ability of hemodialysis patients to secrete tumor necrosis factor (TNF- α), interleukin-1 (IL-1b) and IL-6 by stimulated

monocytes decreased progressively according to length of dialysis therapy. However, the fact that spontaneous production of IL-6 tended to be already elevated in hemodialysis patients suggests that the monocytes might be chronically activated and subsequently refractory to any further stimulation.

Zhang et al. [17] suggested that measuring baseline inflammatory markers could provide information about outcome. Some researchers also suggested monitoring their time-course oscillations. Although the association between longitudinal inflammatory variation and risk prediction has only been examined in a few studies, the repeated elevations of IL-6 may be more predictive than a single elevation [18].

In line with our findings, Oberg et al. [19] looked at plasma IL-6 levels in patients at early stages of CKD [3–5] and found that this interleukin was significantly higher in CKD patients (relative to healthy controls), but there was no link to estimated glomerular filtration rate. As for the correlation of IL-6 with the studied parameters, we found significant negative correlation between IL-6 and both hemoglobin and hematocrit, while no significant correlation could be detected with the rest of the parameters.

This was in agreement with Barreto et al. 2010 study who reported a significant relationship between IL-6 and Hb level ($P < 0.005$). They also reported no significant relationship between IL-6 level and PTH [15].

Our results were contradictory to those reported by Barreto et al, who confirmed an inverse linear relationship between IL-6 levels and the eGFR when the analysis was restricted to pre-dialysis CKD patients at stages 2–5 [15].

To further identify the role of IL-6 in anemia in CKD patients, we performed the ROC curve, which demonstrated a sensitivity of 83.3% and a specificity of 67.7% at a cutoff value for IL-6 of >74.7 ng/l.

6. CONCLUSION

Anemia is a common finding in patients with chronic kidney disease. IL6 is significantly higher in CKD patients in comparison to controls. It also correlates negatively with hemoglobin level and hematocrit. IL6 has a good sensitivity of 83.3% at a cutoff volume of 74.7 ng/l. So, it can be used as a prognostic marker of anemia in CKD

patients. IL-6 could also serve as a therapeutic target in anemic CKD patients.

ETHICAL APPROVAL AND CONSENT

Approval from local ethical committee was obtained (33287/8/19) and a written informed consent was taken from all participants.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. O'Hare AM, Choi AI, Bertenthal D, Bacchetti P, Garg AX, Kaufman JS, et al. Age affects outcomes in chronic kidney disease. *J Am Soc Nephrol.* 2007;18:2758-65.
2. Babitt JL, Lin HY. Mechanisms of anemia in CKD. *J Am Soc Nephrol.* 2012;23:1631-4.
3. Vos FE, Schollum JB, Coulter CV, Doyle TC, Duffull SB, Walker RJ. Red blood cell survival in long-term dialysis patients. *Am J Kidney Dis.* 2011;58:591-8.
4. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. *Cold Spring Harb Perspect Biol.* 2014;6:a016295.
5. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferrremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. *J Clin Invest.* 2004;113:1271-6.
6. Akchurin OM, Kaskel F. Update on inflammation in chronic kidney disease. *Blood Purif.* 2015;39:84-92.
7. Nehus E, Furth S, Warady B, Mitsnefes M. Correlates of resistin in children with chronic kidney disease: the chronic kidney disease in children cohort. *J Pediatr.* 2012;161:276-80.
8. Raj DS, Shah VO, Rambod M, Kovesdy CP, Kalantar-Zadeh K. Association of soluble endotoxin receptor CD14 and mortality among patients undergoing hemodialysis. *Am J Kidney Dis.* 2009;54:1062-71.
9. Andrews NC. Anemia of inflammation: the cytokine-hepcidin link. *J Clin Invest.* 2004;113:1251-3.
10. Łukaszyk E, Łukaszyk M, Koc-Żórawska E, Tobolczyk J, Bodzenta-Łukaszyk A,

- Małyszko J. Iron Status and Inflammation in Early Stages of Chronic Kidney Disease. *Kidney Blood Press Res.* 2015;40:366-73.
11. Shu T, Jing C, Lv Z, Xie Y, Xu J, Wu J. Hepcidin in tumor-related iron deficiency anemia and tumor-related anemia of chronic disease: pathogenic mechanisms and diagnosis. *Eur J Haematol.* 2015;94:67-73.
 12. Nakagawa H, Tamura T, Mitsuda Y, Goto Y, Kamiya Y, Kondo T, et al. Inverse correlation between serum interleukin-6 and iron levels among Japanese adults: A cross-sectional study. *BMC Hematol.* 2014;14:6.
 13. Madu AJ, Ughasoro MD. Anaemia of Chronic Disease: An In-Depth Review. *Med Princ Pract.* 2017;26:1-9.
 14. Raj DS. Role of interleukin-6 in the anemia of chronic disease. *Semin Arthritis Rheum.* 2009;38:382-8.
 15. Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. *Kidney Int.* 2010;77:550-6.
 16. Malaponte G, Bevelacqua V, Fatuzzo P, Rapisarda F, Emmanuele G, Travali S, et al. IL-1beta, TNF-alpha and IL-6 release from monocytes in haemodialysis patients in relation to dialytic age. *Nephrol Dial Transplant.* 2002;17:1964-70.
 17. Zhang W, He J, Zhang F, Huang C, Wu Y, Han Y, et al. Prognostic role of C-reactive protein and interleukin-6 in dialysis patients: A systematic review and meta-analysis. *J Nephrol.* 2013;26:243-53.
 18. Meuwese CL, Stenvinkel P, Dekker FW, Carrero JJ. Monitoring of inflammation in patients on dialysis: Forewarned is forearmed. *Nat Rev Nephrol.* 2011;7:166-76.
 19. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. *Kidney Int.* 2004;65:1009-16

© 2022 Esmail et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/85120>